SEMA4D and pancreatic neoplasm: SEMA4D has been confirmed to be expressed at high levels in a variety of tumors, including prostate cancer, colon cancer, breast cancer, oral cancer, lung cancer, pancreatic cancer, head and neck carcinoma, and soft tissue sarcoma (2).